July 25th 2024
Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.
This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.
Read More